Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
ACQUIRED COMPANY
 
My Lists

Questcor Pharmaceuticals  (Stock symbol: QCOR ) Acquired by Mallinckrodt Pharmaceuticals (2014 $ 5,600,000,000 )

3260 Whipple Road
Union City, CA 94587
USA
(510)-732-5551
Website Company Summary Management Team
Board

Outside board: (May no longer be on the board) Louis E Silverman (Marina Medical Billing Service CEO) Stephen C Farrell (PolyMedica Former President) G Kelly Martin (Elan Pharmaceuticals President/CEO) Agnus C Russell (Shire CEO) Scott Whitcup (Allergan EVP R&D and Chief Scientist) Neal C Bradsher (Broadwood Capital) Virgil Thompson (Chimeric Therapies CEO)
Former outside board: Howard Palefsky (Montreux Equity Partners);  David Young (AGI Therapeutics President) Robert J Rubin (Georgetown University‚Äôs School of Medicine clinical professor) Mitchell J Blutt (Consonance Capital CEO) Greg Lapointe (Sigma-Tau Pharmaceuticals COO) Robert Allnut (CORTEX Pharmaceuticals);  Digby Barrios (consultant);  Brian C Cunningham Albert Hansen (Sanders Morris Harris) Frank Sasinowski (FDA consultant);  Jon S Saxe (Protein Design Labs,Pres) John Spitznagel (Roberts Pharmaceutical CEO);  Roger Stoll (Ohmeda CEO)
Company

Business description: Questcor Pharmaceuticals, Inc. is a specialty pharmaceutical company that acquires, markets and sells brand name prescription drugs through a U.S. direct sales force and international distributors. Questcor currently markets five products in the U.S.: Nascobal(R), the only prescription nasal gel formulation of Cyanocobalamin USP (Vitamin B-12), that is approved for patients with severe deficiencies of Vitamin B-12 caused by Crohn's Disease and MS; HP Acthar(R) Gel, an injectable drug that is commonly used in treating patients with infantile spasm and is approved for the treatment of certain central nervous system disorders with an inflammatory component including the treatment of flares associated with Multiple Sclerosis; Ethamolin(R), an injectable drug used to treat enlarged weakened blood vessels at the entrance to the stomach that have recently bled, known as esophageal varices; Glofil(R)-125, which is an injectable agent that assesses how well the kidney is working by measuring glomerular filtration rate, or kidney function; and VSL#3(R), a patented probiotic marketed as a dietary supplement, to promote normal gastrointestinal (GI) function.
Partners include: Rigel Pharmaceuticals;  Crinos Industria Farmacobiologica;  CSC Pharmaceuticals;  Dainippon Pharmaceutical;  Laboratories Silesia;  Pharm-Eco Labs;  Roberts Pharmaceuticals
Capital

Capital raised: 39.9M
Ownership: Acquired by Mallinckrodt Pharmaceuticals (2014 $ 5,600,000,000 )
Stock Symbol: QCOR
Corporate investors: Abbott Laboratories

Last Tweets


 

Last Mentions


Overview
Record updated: Dec 2016
Sector: Medical
Year Founded: 1990
Headcount: 501-600 as of May 2013
Capital Raised: 39.9M
Ownership: Acquired by Mallinckrodt Pharmaceuticals (2014 $ 5,600,000,000 )
Stock Symbol: QCOR